Background: The concentration of free fatty acid (FFA) in breast milk is the key indicator for milk fat degradation during storage and handling. Inaccurate measurements of FFA are commonly seen in conventional methods due to contamination by the dominant triglyceride fraction.
IMPROVING THE DETECTION OF FETAL GROWTH RESTRICTION; EVALUATION OF USER EXPERIENCE OF AN INTERACTIVE EDUCATIONAL PROGRAM
A four and a half hour face-to-face workshop has been developed to provide education to clinicians caring for pregnant women in order to improve detection and management of FGR, resulting in improvement in clinical practice and pregnancy outcomes. Ten workshops have been run in Victoria to date (11 further workshops planned).
Methods: Evaluation of participant knowledge and confidence of the 11 learning objectives was undertaken using a paper based or on-line survey administered immediately pre and post workshop.
Results: 304 participants have attended the 10 workshops held to date. Evaluation surveys were completed by 168 (55%); including 137 midwives and 31 doctors. Responses show an increase in participants' confidence and knowledge across all learning objectives post workshop. Overall, 38% of participants reported being "confident or extremely confident" in best practice for the detection and clinical management of FGR prior to the program and this increased to 87% post-workshop. 84% of participants indicated they would change some aspect of their clinical practice following the workshop. Participants reported high levels of satisfaction (>90%) for all aspects of the workshop including quality of facilitators, learning resources, relevant content and presentation format.
Conclusions: The FGR education program appears to be beneficial in improving clinician knowledge and confidence in the detection and management of FGR. King Edward Memorial Hospital, Perth, Australia Email: jayna-lee.garratt@health.wa.gov.au Background: Chronic kidney disease (CKD) affects 3.3% of pregnancies and even mild disease is associated with adverse maternal and neonatal outcomes, including preeclampsia, declining renal function, anaemia, preterm birth and perinatal death. We present a case of a 30-year-old gravida 7, para 2 with CKD secondary to diabetic nephropathy, requiring erythropoietin for management of anaemia.
PREECLAMPSIA IN A PATIENT WITH DIABETIC NEPHROPATHY: CHALLENGES OF MANAGING PREGNANCY IN CHRONIC KIDNEY DISEASE
Methods: A case study was performed through review of medical notes and laboratory results.
Results: A 30-year-old gravida 7, para 2 presented for antenatal care at 8 + 4 weeks gestation. Obstetric history included two previous Caesarean sections, the first at 32 weeks for fetal distress in the presence of fetal ventricular septal defect, and the second at 34 weeks for preeclampsia. Past medical history included type 1 diabetes mellitus, diabetic nephropathy and non-proliferative diabetic retinopathy. She had commenced methyldopa for newonset hypertension at 8 weeks. Investigations revealed normocytic anaemia, nephrotic-range proteinuria, mild renal impairment and HbA1c of 8.3%. She was commenced on aspirin at 8 + 4 weeks. From 22 + 3 weeks she received weekly erythropoietin for anaemia secondary to CKD. Her renal function declined throughout pregnancy. At 27 + 2 weeks she developed preeclampsia, leading to further deterioration in her renal function, and decision was made for delivery via Caesarean section at 28 + 3 weeks.
Conclusion: Our case explores the challenges of managing pregnancy in patients with CKD, including the difficulties of diagnosing preeclampsia in this population. It highlights the importance of tertiary, multidisciplinary management to improve perinatal outcomes. A review of current evidence for the management of CKD in pregnancy will be presented.
